Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) on Thursday announced the launch of Prucalopride Tablets, a generic version of Motegrity.
The US Food and Drug Administration (FDA) has granted ANI 180-day marketing exclusivity for its Prucalopride Tablets.
This launch follows the FDA's approval of ANI's Abbreviated New Drug Application (ANDA).
ANI's Prucalopride Tablets are expected to compete in a market with approximately USD168m in annual sales.
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical